GSK Will Pay $185 Million to Direct, Indirect Purchasers of Flonase Nasal Spray

Drugmaker GlaxoSmithKline Dec. 20, 2012, said that it will pay a total of $185 million to direct and indirect purchasers of the nasal spray Flonase (fluticasone propionate) (In re Flonase Antitrust Litigation).

The settlements end the purchasers’ claims against GSK for various antitrust violations arising from conduct allegedly delaying the entry of generic Flonase to the market. Under the settlement, GSK will pay the direct purchaser class—which includes American Sales Company Inc., Meijer Inc., and Meijer Distribution Inc.—$150 million and the indirect purchaser class—which includes various health plans—$35 million.

Judge Anita B. Brody of the U.S. District Court ...